Lind Global files 13G/A: 212,500 warrants in Silexion (SLXN)
Rhea-AI Filing Summary
Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class. The holdings consist of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants, each subject to an exercise limitation that prevents exercise if such exercise would raise beneficial ownership above 9.9%. The filing lists Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton as reporting persons and shows sole voting and dispositive power for 212,500 instruments.
Positive
- None.
Negative
- None.
Insights
13G/A discloses sub-5% warrant position with a 9.9% exercise cap.
The amendment reports 212,500 warrants held by Lind Global Fund III LP and related reporting persons, shown as 4.96% of the class. The filing specifies sole voting and dispositive power for the reported amount.
The warrants are split into 106,250 Series A-1 and 106,250 Series A-2 instruments and include a contractual limitation preventing exercise that would push ownership above 9.9%. Subsequent disclosures may clarify timing or conversion mechanics if exercised.
Position is a nondispositive passive holding below 5% threshold but expressed via warrants.
The filing is an ownership disclosure under Schedule 13G/A that classifies the position at 4.96%. The holdings are warrants rather than currently outstanding common shares, and exercise is conditionally capped.
Cash-flow treatment and conversion timing are not detailed in the excerpt; any market impact depends on whether and when warrants convert into ordinary shares subject to the 9.9% cap.
Key Figures
Key Terms
Series A-1 Warrants financial
Series A-2 Warrants financial
Beneficial ownership regulatory
Sole dispositive power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.